Mounjaro vs Wegovy: What Happens When You Put Them Head-to-Head?

Sep 24

4 min read

Updated: Oct 10

Two identical, unbranded clear glass medicine vials side by side on a clean white clinical surface, representing a head-to-head comparison

If you've been thinking about weight-loss medication, you've probably heard two names a lot: Wegovy and Mounjaro. Both are injections. Both help people lose weight. But which one works better? For a long time, nobody knew for sure, because the two drugs had never been tested against each other in the same study, on the same people, at the same time.

Now they have. And the results tell an interesting story — not just about which drug wins, but about how "winning" isn't always simple.

A quick refresher: what these drugs actually are

Wegovy's active ingredient is called semaglutide. Mounjaro's is called tirzepatide. Both belong to a family of medicines called GLP-1 receptor agonists. GLP-1 is a hormone your gut makes naturally after you eat. It tells your brain "I'm full" and slows down how fast your stomach empties. These drugs copy that hormone, so your body gets a stronger, longer-lasting "I'm full" signal.

Tirzepatide does something extra. It also copies a second hormone called GIP. Scientists think that's part of why it tends to produce bigger results. Think of semaglutide as pressing one "fullness" button, and tirzepatide as pressing two.

The trial that finally compared them directly

The study is called SURMOUNT-5. Researchers took 751 adults with obesity or overweight and split them into two groups. One group got tirzepatide. The other got semaglutide, both at their strongest approved doses. Nobody knew in advance which drug would do better — that's the point of a fair test. The trial ran for 72 weeks, which is a little under a year and a half.

Here's what happened. People taking tirzepatide lost an average of 20.2% of their body weight — about 50 pounds (23 kilograms), on average. People taking semaglutide lost an average of 13.7% of their body weight — about 33 pounds (15 kilograms). To put that another way, tirzepatide produced roughly 47% more weight loss than semaglutide in this study.

The gap showed up in other ways too. Researchers looked at how many people hit certain weight-loss milestones. Among people taking tirzepatide, 31.6% lost at least a quarter of their starting body weight. Among people taking semaglutide, only 16.1% did. Tirzepatide also produced a slightly bigger drop in blood sugar levels (measured by something called HbA1c, a test that shows your average blood sugar over the past few months).

A separate, larger analysis that combined SURMOUNT-5 with other head-to-head studies found the same pattern: across the board, tirzepatide edged out semaglutide on weight loss, at every threshold researchers checked (losing at least 10%, 15%, or 20% of body weight).

But here's the part that matters just as much

Bigger results don't always mean a better choice for everyone. When researchers looked closely at safety, the picture got more complicated.

Common side effects — nausea, vomiting, diarrhea, constipation, stomach pain — were about the same between the two drugs. Neither one was clearly gentler on the stomach than the other. And when it came to people quitting the medication because of side effects, there was no real difference between the two groups.

But serious adverse events — meaning side effects serious enough to need medical attention or hospital care — were more common with tirzepatide. In the combined analysis, 5.7% of people on tirzepatide had a serious adverse event, compared to 2.9% of people on semaglutide. That's about twice as many. Researchers aren't yet sure exactly why, and this doesn't mean tirzepatide is unsafe — both drugs have been used by millions of people and are approved by regulators as safe options. It does mean the drug with the bigger average weight loss also showed a higher rate of serious problems in this comparison.

So which one is "better"?

That depends on what you're weighing up. If your main goal is maximum weight loss and you're working closely with a doctor, tirzepatide's results are hard to ignore. If you want a slightly gentler track record on serious side effects, or you simply respond better to one hormone pathway than two, semaglutide might suit you better. Cost and access matter too — in the UK, availability of each drug through the NHS or privately can differ depending on your BMI, health conditions, and local prescribing rules.

The honest answer is that this isn't a story of one drug being "correct" and the other being "wrong." It's a trade-off between how much weight a drug is likely to help you lose and how it fits your own health picture. That's exactly the kind of decision a GP or weight-management specialist can help you think through, using your own medical history — not just an average from a research study.